We report a 30-year-old patient with therapy-refractory T-ALL undergoing unrelated allogeneic PBSCT. He developed severe tumor lysis syndrome (TLS) with extreme biochemical changes, cardiac and neurological symptoms and dialysis-dependent acute renal failure after TBI (4 Gy) on the first day of reduced intensity conditioning (RIC) for unrelated allogeneic PBSCT. The patient's clinical condition was stabilized after beginning daily hemodialysis and treatment for disturbed electrolytes, metabolic acidosis and plasma coagulation, as well as reduction of uric acid by rasburicase. The conditioning therapy and the allogenic PBSCT were scheduled according to the preparative regimen. According to our knowledge, severe TLS induced by 4 Gy TBI has not been reported so far. Regimen-related toxicity using RIC regimen was mild, allowing 30-50% of the patients to have an entirely outpatient transplantation. However, we would like to point out that severe TLS could also complicate PBSCT using RIC regimens in patients with relatively radiation-sensitive malignancies and high tumor burden. Bone Marrow Transplantation (2003) 31, 935-937. 
We report a 30-year-old patient with therapy-refractory T-ALL undergoing unrelated allogeneic PBSCT. He developed severe tumor lysis syndrome (TLS) with extreme biochemical changes, cardiac and neurological symptoms and dialysis-dependent acute renal failure after TBI (4 Gy) on the first day of reduced intensity conditioning (RIC) for unrelated allogeneic PBSCT. The patient's clinical condition was stabilized after beginning daily hemodialysis and treatment for disturbed electrolytes, metabolic acidosis and plasma coagulation, as well as reduction of uric acid by rasburicase. The conditioning therapy and the allogenic PBSCT were scheduled according to the preparative regimen. According to our knowledge, severe TLS induced by 4 Gy TBI has not been reported so far. Regimen-related toxicity using RIC regimen was mild, allowing 30-50% of the patients to have an entirely outpatient transplantation. However, we would like to point out that severe TLS could also complicate PBSCT using RIC regimens in patients with relatively radiation-sensitive malignancies and high tumor burden. Bone Marrow Transplantation (2003) 31, 935-937. doi:10.1038/sj.bmt.1704025 Keywords: tumor lysis syndrome; total body irradiation; reduced intensity conditioning regimen; allogeneic hematopoietic stem cell transplantation; T-ALL Tumor lysis syndrome (TLS) may be a severe complication during therapy of hematological and oncological diseases. It is caused by massive malignant cell destruction and consecutive release of intracellular substances and their metabolism. The typical laboratory constellation and the onset of various organ impairments are features of this potentially life-threatening complication. The risk of developing TLS varies depending on cell proliferation rate and tumor cell mass. The highest incidence of TLS is known to occur after acute leukemia therapy, high-grade NHL, especially Burkitt's lymphoma and myeloproliferative diseases, [1] [2] [3] [4] but has also been reported in breast cancer 1,2 and gut adenocarcinoma. 1, 2 In patients receiving chemotherapy, the characteristic laboratory constellation can also be found without any clinical changes. 4, 5 Due to a shift of electrolyte balance and uric acid production from intracellular nucleic acids, a characteristic biochemical profile and subsequent organ impairments may occur. [1] [2] [3] Cardiac function can be disturbed by hyperkalemia and hypocalcemia. The ECG shows various and potentially malignant types of arrhythmia together with a wide range of sinus-node dysfunctions and conduction disturbances. 1 Neurological symptoms, which are regularly found, are paresthesia, paresis, cephalgia, lethargia and muscular cramps. 1 Renal impairment is caused by precipitation of both calcium phosphate and uric acid in the glomerulae and tubuli. Acute renal failure (ARF) leading to hemodialysis dependence may be the consequence. 1 Elevated LDH before therapy, prior renal impairment and the use of potential nephrotoxic drugs are known risk factors for TLS and ARF. [1] [2] [3] In this report, we present the peracute onset of severe TLS complicated by renal failure only 2 h after 4 Gy fractionated TBI of a reduced intensity conditioning (RIC) regimen for allogeneic PBSCT in a patient with refractory T-ALL.
Case report
A 30-year-old man suffering from refractory T-ALL was admitted to the hospital for allogeneic PBSCT. He had endured several chemotherapy regimens as well as irradiation of cranium (total dose 24 Gy) and mediastinum (total dose 60 Gy) since diagnosis. The patient's laboratory findings showed leukocytosis (20 300/ml), anemia (9.6 g/dl) and thrombocytopenia (9000/ml). Aspartate and alanine aminotransferases were 82 and 71 U/l, respectively. Alkaline phosphatase was 575 U/l and gamma glutamyl transferase 212 U/l. Lactate dehydrogenase (3090 U/l), uric acid (10.7 mg/dl) and C-reactive protein (3.1 mg/dl) were increased. Other biochemical values, including coagulation, were within the normal range. Body temperature was 36.61C, while pulse and respiration rates were 104 and 14, respectively. The blood pressure was 140/80 mmHg. The patient's medication at the time of admission consisted of cotrimoxazole, pantozole (40 mg) and Amphomoronale suspension. The patient had etoposide 50 mg daily orally until the day of admission. A reduced intensity protocol was planned in preparation for transplantation. The regimen included TBI (given in a dose of 4 Â 2 Gy in 2 days, days À7 and À6, dose rate 29.8 cGy/min, interfraction interval 6 h, without schielding), fludarabine (30 mg/m 2 over 4 days, from days À6 to À3) and ATG (20 mg/kg bw over 2 days, days À3 and À2). Additional medications included immunoglobulin, cyclosporine, methotrexate, aciclovir and fluconazole. At 2 h after the second TBI fraction, the patient complained about muscular cramps of the lower limb, paresthesia of upper and lower limb, cephalgia and progredient lethargia. Owing to peripheral tachycardia an ECG was performed. It showed supraventricular tachycardia and enlarged ventricular complexes, changes of ST segment and ventricular extrasystoles. The laboratory findings indicated massive hyperkalemia (8.30 mmol/l) and hypocalcemia (1.58 mmol/ l), while the phosphate level was 18.70 mg/dl ( Table 1 ). The renal parameters were rising: creatinine -2.50 mg/dl, urea -91.1 mg/dl, LDH -11 100 U/l and uric acid -12.0 mg/dl. The venous acid-base check showed metabolic acidosis: pH -7.28, BE -10.5 and bicarbonate -14.7 mmol/l. Summarizing, severe TLS was diagnosed. The patient was supervised by cardiac monitor. Due to the massive shift of electrolytes and the metabolic acidosis, hemodialysis was begun immediately. To rebalance the electrolytes, calcium and potassium-binders were given intravenously in high doses. Bicarbonate was applied to compensate for metabolic acidosis. We started dopamine in renal dose and performed hydration under the supervision of central venous pressure. The elevated uric acid was reduced by giving uricase at 0.2 mg/kg bw for five consecutive days. After hemodialysis, the patient's cardiac and neurological complaints declined and the ECG normalized. The electrolytes and acid-base metabolism could be stabilized, but anuria and dialysis dependence persisted. The conditioning therapy could be continued according to the protocol.
Discussion
TLS, caused by massive destruction of malignant cells after cytostatic therapy, is characterized by a shift of electrolytes with hyperkalemia, hyperphosphatemia and hypocalcemia, accumulation of uric acid and subsequent impairments in various organs. It is a severe therapy-related complication of hematological and oncological diseases. [1] [2] [3] [4] A high incidence of TLS is described in diseases with high cell proliferation rate or tumor cell mass and diverse additional riskfactors for developing this complication have been reported. [1] [2] [3] [4] Our patient had a relatively radiation-sensitive T-ALL with high tumor burden; he developed a peracute, severe TLS with characteristic biochemical changes, cardiac and neurological symptoms together with dialysis-dependent ARF shortly after application of 4 Gy total body irradiation during a RIC regimen for an allogeneic PBSCT. Laboratory findings during the conditioning regimen (days À7 to À2). Hemodialysis was introduced and performed daily after receiving 4 pm laboratory results on day À7. Rasburicase 0.2 mg/kg bw was given daily from days À7 to À3.
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Although acute onset of TLS after TBI in a transplant setting has already been reported, 6, 7 we are not aware of any previous case of life-threatening TLS after 4 Gy of TBI as part of the RIC regimen for allogeneic PBSCT. However, this severe complication could also have happened if the patient was destined to undergo full myeloablative transplant with the TBI scheduled first before the chemotherapy. In addition, the dexamethasone given two times 4 mg as antiemetic therapy on day À7 could have contributed to the TLS since glucocorticoids have been reported to produce TLS in rare occasions. 8 Despite the refractory and active leukemia, elevated LDH and uric acid characterizing the risk constellation on admission, the fulminant development was surprising. Due to normal renal parameters, the patient received allopurinol for prophylaxis. Retrospectively, the elevated LDH and uric acid on admission could have been interpreted as TLS without clinical symptoms during the etoposide chemotherapy, applied in the immediate pre-transplant period. In our case the characteristic biochemical parameters and the typical organ involvement enabled fast diagnosis and immediate introduction of hemodialysis. Despite persisting dependance on hemodialysis, the clinical status of the patient could be stabilized and the conditioning therapy could be continued according to the protocol. However, the potential life-threatening character of TLS necessitates supervision in an intensive care unit in the acute situation. Permanent cardiac monitoring, sufficient hydration and electrolyte compensation must be started early. In order to prevent further precipitation of calcium phosphate and uric acid, the pH of serum and urine has to be alkaline. 1, 4 Uric acid must be eradicated fast and permanently to prevent acute renal failure.
In conclusion, it is necessary to identify risk constellations, especially in patients with active disease, prior to starting the conditioning therapy before HSCT and to perform sufficient prophylaxis and supervision of clinical status and laboratory parameters. We suggest preventive hydration with urine alkalization and administration of rasburicase if a similar patient comes up for a TBI-first regimen. The use of RIC regimens in allogeneic HSCT is gaining widespread acceptance due to low regimen-related toxicity.
9-11 Based on our case observation, we would like to point out that severe TLS can also complicate an approach like this in defined risk constellations.
